1-11 of 11
Pablo Umaña
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade

Annapaola Mariniello, Tahseen H. Nasti, Daniel Y. Chang, Masao Hashimoto, Sakshi Malik, Daniel McManus, Judong Lee, Donald McGuire, Maria A. Cardenas, Pablo Umana, Valeria Nicolini, Rustom Antia, Ananya Saha, Zachary Buchwald, Haydn Kissick, Ehsan Ghorani, Silvia Novello, Dario Sangiolo, Giorgio V. Scagliotti, Suresh S. Ramalingam, Rafi Ahmed
Journal: Clinical Cancer Research
Clin Cancer Res (2023)
https://doi.org/10.1158/1078-0432.CCR-23-1316
Published: 22 November 2023
View article titled, Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade
Open the PDF for Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade in another window
Includes: Supplementary data
Journal Articles

Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies

Gabrielle Leclercq-Cohen, Nathalie Steinhoff, Llucia Albertí Servera, Sina Nassiri, Sabrina Danilin, Emily Piccione, Emilio Yángüez, Tamara Hüsser, Sylvia Herter, Stephan Schmeing, Petra Gerber, Petra Schwalie, Johannes Sam, Stefanie Briner, Sylvia Jenni, Roberta Bianchi, Marlene Biehl, Floriana Cremasco, Katerina Apostolopoulou, Hélène Haegel, Christian Klein, Pablo Umaña, Marina Bacac
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4449–4463.
https://doi.org/10.1158/1078-0432.CCR-22-3667
Published: 01 November 2023
View article titled, Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Open the PDF for Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies in another window
Includes: Supplementary data
Journal Articles

CD40 Agonist Targeted to Fibroblast Activation Protein α Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors

Sara Labiano, Vincent Roh, Céline Godfroid, Agnès Hiou-Feige, Jackeline Romero, Eva Sum, Moritz Rapp, Gael Boivin, Tania Wyss, Christian Simon, Jean Bourhis, Pablo Umaña, Christine Trumpfheller, Genrich V. Tolstonog, Marie-Catherine Vozenin, Pedro Romero
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (14): 4054–4065.
https://doi.org/10.1158/1078-0432.CCR-20-4717
Published: 15 July 2021
View article titled, CD40 Agonist Targeted to Fibroblast Activation Protein α Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors
Open the PDF for CD40 Agonist Targeted to Fibroblast Activation Protein α Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors in another window
Includes: Supplementary data
Journal Articles

Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity

Eva Sum, Moritz Rapp, Philipp Fröbel, Marine Le Clech, Harald Dürr, Anna Maria Giusti, Mario Perro, Dario Speziale, Leo Kunz, Elena Menietti, Peter Brünker, Ulrike Hopfer, Martin Lechmann, Andrzej Sobieniecki, Birte Appelt, Roberto Adelfio, Valeria Nicolini, Anne Freimoser-Grundschober, Whitney Jordaan, Sara Labiano, Felix Weber, Thomas Emrich, François Christen, Birgit Essig, Pedro Romero, Christine Trumpfheller, Pablo Umaña
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (14): 4036–4053.
https://doi.org/10.1158/1078-0432.CCR-20-4001
Published: 15 July 2021
View article titled, Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity
Open the PDF for Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity in another window
Includes: Supplementary data
Journal Articles

T-cell–engaging Therapy for Solid Tumors

Maria de Miguel, Pablo Umana, Ana Luiza Gomes de Morais, Victor Moreno, Emiliano Calvo
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6): 1595–1603.
https://doi.org/10.1158/1078-0432.CCR-20-2448
Published: 15 March 2021
View article titled, T-cell–engaging Therapy for Solid Tumors
Open the PDF for T-cell–engaging Therapy for Solid Tumors in another window
Journal Articles

CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies

Marina Bacac, Sara Colombetti, Sylvia Herter, Johannes Sam, Mario Perro, Stanford Chen, Roberta Bianchi, Marine Richard, Anne Schoenle, Valeria Nicolini, Sarah Diggelmann, Florian Limani, Ramona Schlenker, Tamara Hüsser, Wolfgang Richter, Katharine Bray-French, Heather Hinton, Anna Maria Giusti, Anne Freimoser-Grundschober, Laurent Lariviere, Christiane Neumann, Christian Klein, Pablo Umaña
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (19): 4785–4797.
https://doi.org/10.1158/1078-0432.CCR-18-0455
Published: 01 October 2018
View article titled, CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Open the PDF for CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies in another window
Includes: Multimedia, Supplementary data
Journal Articles

In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing

Steffi Lehmann, Ramanil Perera, Hans-Peter Grimm, Johannes Sam, Sara Colombetti, Tanja Fauti, Linda Fahrni, Teilo Schaller, Anne Freimoser-Grundschober, Jörg Zielonka, Szymon Stoma, Markus Rudin, Christian Klein, Pablo Umana, Christian Gerdes, Marina Bacac
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (17): 4417–4427.
https://doi.org/10.1158/1078-0432.CCR-15-2622
Published: 31 August 2016
View article titled, <em>In Vivo</em> Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing
Open the PDF for <em>In Vivo</em> Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing in another window
Includes: Multimedia, Supplementary data
Journal Articles

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

Marina Bacac, Tanja Fauti, Johannes Sam, Sara Colombetti, Tina Weinzierl, Djamila Ouaret, Walter Bodmer, Steffi Lehmann, Thomas Hofer, Ralf J. Hosse, Ekkehard Moessner, Oliver Ast, Peter Bruenker, Sandra Grau-Richards, Teilo Schaller, Annette Seidl, Christian Gerdes, Mario Perro, Valeria Nicolini, Nathalie Steinhoff, Sherri Dudal, Sebastian Neumann, Thomas von Hirschheydt, Christiane Jaeger, Jose Saro, Vaios Karanikas, Christian Klein, Pablo Umaña
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (13): 3286–3297.
https://doi.org/10.1158/1078-0432.CCR-15-1696
Published: 30 June 2016
View article titled, A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Open the PDF for A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors in another window
Includes: Multimedia, Supplementary data
Journal Articles

Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy

Valeria Gonzalez-Nicolini, Sylvia Herter, Sabine Lang, Inja Waldhauer, Marina Bacac, Michaela Roemmele, Esther Bommer, Olivier Freytag, Erwin van Puijenbroek, Pablo Umaña, Christian A. Gerdes
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (10): 2453–2461.
https://doi.org/10.1158/1078-0432.CCR-14-2579
Published: 12 May 2016
View article titled, Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy
Open the PDF for Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy in another window
Journal Articles

GA201: A Novel Humanized and Glycoengineered Anti-EGFR Antibody—Response

Christian A. Gerdes, Pablo Umaña
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (4): 1055.
https://doi.org/10.1158/1078-0432.CCR-13-2699
Published: 16 February 2014
View article titled, GA201: A Novel Humanized and Glycoengineered Anti-EGFR Antibody—Response
Open the PDF for GA201: A Novel Humanized and Glycoengineered Anti-EGFR Antibody—Response in another window
Journal Articles

GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab

Christian A. Gerdes, Valeria Gonzalez Nicolini, Sylvia Herter, Erwin van Puijenbroek, Sabine Lang, Michaela Roemmele, Ekkehard Moessner, Olivier Freytag, Thomas Friess, Carola H. Ries, Birgit Bossenmaier, Hans Joachim Mueller, Pablo Umaña
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (5): 1126–1138.
https://doi.org/10.1158/1078-0432.CCR-12-0989
Published: 03 March 2013
View article titled, GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior <em>In Vivo</em> Efficacy Compared with Cetuximab
Open the PDF for GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior <em>In Vivo</em> Efficacy Compared with Cetuximab in another window
Includes: Supplementary data